The FDA Removed Its Black Box Warning on Menopause Hormone Therapy — Here's What Changed
In 2026, the FDA approved updated labeling that removes longstanding boxed-warning language — the agency's most serious safety alert — from several menopausal hormone therapy products, including systemic estrogen and vaginal estrogen. The change reflects a re-reading of decades of safety data, not a declaration that hormone therapy is risk-free; a personalized evaluation with a licensed provider is still where the decision starts.
What actually changed
In early 2026, the FDA approved label updates for several menopausal hormone therapy products that remove specific boxed-warning language addressing cardiovascular disease, breast cancer and probable dementia. It followed an FDA-convened expert panel review and formal steps the agency announced in late 2025. The boxed warning — the FDA's most serious labeling alert, reserved for risks considered significant enough to influence a prescribing decision — is being narrowed, not eliminated. Updated labels still discuss cardiovascular, clotting and other risks; they no longer lead with language many clinicians and patients had come to read as "hormone therapy is dangerous for most people," a read the agency and many OB-GYNs say overstated the original research.
Why the warning existed in the first place
The boxed warning dates to 2003, following early results from the Women's Health Initiative (WHI) — a large federal study that linked combined hormone therapy to increased risk of breast cancer, heart disease, stroke and blood clots. Those findings led to a sharp, long-lasting drop in hormone therapy use nationwide. In the decades since, follow-up analyses of the same WHI data — accounting for a patient's age and years since menopause onset — found the original findings had been applied too broadly, especially to younger, recently menopausal women and to low-dose vaginal formulations with minimal systemic absorption.
What's still true — and what to still ask about
This label change is not a blanket declaration of safety. Venous thromboembolism (blood clots), ischemic stroke and gallbladder disease are still listed as associated risks, and professional bodies like ACOG have been explicit that their clinical guidance hasn't changed: hormone therapy still calls for an individualized conversation that weighs your personal and family history (including breast cancer), age, time since menopause, and the specific type and route of hormone therapy being considered. If you have a personal or strong family history of breast cancer, a prior blood clot, or cardiovascular disease, that history still matters to the decision — the labeling update doesn't change that.
Vaginal estrogen vs. systemic HRT: different products, different risk
Not all hormone therapy carries the same risk profile, and the 2026 update reflects that. Low-dose vaginal estrogen — often used for symptoms like vaginal dryness and urinary discomfort — has minimal systemic absorption and is generally considered to carry a different, often lower, risk profile than oral or transdermal estrogen taken for broader menopause symptoms like hot flashes and sleep disruption. Several clinicians quoted in national coverage of this label change have called for the vaginal and systemic categories to be evaluated — and discussed with patients — separately, rather than lumped together under one "HRT" label.
How Roots approaches hormone therapy for menopause
At Roots, menopause-related hormone therapy starts the same way every hormone protocol does here: with bloodwork, not a template. Our clinical team reviews your labs, symptoms, personal and family health history, and goals before recommending any approach — and continues to monitor and adjust as your body changes. The FDA's labeling update may open the conversation for women who avoided hormone therapy because of the older warning, but it doesn't replace that conversation. Whether hormone therapy is appropriate, which formulation and route make sense, and how it should be monitored remain decisions made with your provider, not a label. Outcomes vary, and candidacy is confirmed at consultation.
Frequently asked questions
Did the FDA remove the black box warning on hormone replacement therapy?
Yes. In early 2026, the FDA approved label updates for several menopausal hormone therapy products that remove specific boxed-warning language about cardiovascular disease, breast cancer and dementia risk. The boxed warning itself isn't gone entirely for every product — it's narrower than it was.
Why did the FDA add the warning in 2003 in the first place?
It followed early results from the Women's Health Initiative, a large federal study that linked hormone therapy to breast cancer, heart disease, stroke and blood clots. Later analysis found those early findings had been applied too broadly, particularly to younger, recently menopausal women and to low-dose vaginal estrogen.
Does this mean hormone therapy is risk-free now?
No. Medical groups including ACOG have said their clinical guidance hasn't changed — hormone therapy can still carry risks like blood clots and stroke for some women, and candidacy still depends on personal and family health history. The labeling update reflects a re-reading of safety data, not a guarantee of safety for everyone.
Is vaginal estrogen the same as systemic hormone therapy?
No. Low-dose vaginal estrogen has minimal systemic absorption and is generally considered to carry a different risk profile than oral or transdermal estrogen used for broader menopause symptoms like hot flashes. The two are increasingly discussed as separate categories with separate risk conversations.
How does Roots decide if hormone therapy is right for me?
Through bloodwork, a review of your personal and family health history, and a conversation about your symptoms and goals with our clinical team — not a standard protocol. Your plan is built around your labs and monitored over time, with outcomes varying from person to person.